Sam Ghilardi 3/3/26 Sam Ghilardi 3/3/26

Watertown's Emerging Rare Blood Disorder Therapy Cluster, Warning Signs For Werewolf, and Fallout for Disc Medicines-Watertown Bio News RoundUp

Join us next week in Charting Watertown’s Life Science Future

Sam Ghilardi 2/17/26 Sam Ghilardi 2/17/26

An FDA Rejection, A Big Pharma Purchase, and Charting Watertown's Life Science Future -Watertown Bio News RoundUp

Plus another $10 million in VC raised, Souffle inks a partnership with Bayer, and more

Sam Ghilardi 2/3/26 Sam Ghilardi 2/3/26

A bright spot during a turbulent time for the industry.

Sam Ghilardi 1/20/26 Sam Ghilardi 1/20/26

2025 Funding numbers are in, 2026 early raises, Lyra Therapeutics runs out of time and more

Sam Ghilardi 1/6/26 Sam Ghilardi 1/6/26

Neumora's positive clinical data , new tenants at the Arsenal, and more

Sam Ghilardi 12/16/25 Sam Ghilardi 12/16/25

A Multi-Million dollar public offering, the developing race for a dupilumab alternative, business awards, and more.

Sam Ghilardi 12/2/25 Sam Ghilardi 12/2/25

Stratus Therapeutics winding down, Consider the ALS TDI for Giving Tuesday, and more

Sam Ghilardi 11/18/25 Sam Ghilardi 11/18/25

Neumora's Wegovy alternative, Dyno announces manufacturing pact, and more

Sam Ghilardi 11/4/25 Sam Ghilardi 11/4/25

Soufflé Therapeutics Launches from Stealth, Disc and Werewolf receive FDA priority, Affini-T may be winding down.